About

The Company

Founded in Palo Alto, California, in 1998, Dx-Sys specializes in providing reagents and services for Immunodiagnostics worldwide. We have over 19 years of ongoing partnerships with several Biotech companies. We strive to develop, manufacture and market cost-effective immunodiagnostic products without compromising their quality. Our team of scientists has extensive combined experience in antigen development, bioprocessing, cell culture, hybridoma development, assay development, protein purification, diagnostic kit development and pre-clinical pharmaceutical formulations and animal studies. We are committed to satisfying our customers’ needs by ensuring the best quality of every product we manufacture at an affordable price.   Our mission is to become the preferred and trusted partner for Biotech companies for all their immunodiagnostic and pharmaceutical needs.

The Team

Subbarao Gunupudi, Ph.D., Founder & CEO

Subbarao founded Dx-Sys Inc in 1998 and has over 35 years of experience in the immunodiagnostics industry. After receiving his doctorate degree in Biochemistry from the Indian Institute of Science, he began his post-doctoral research as an assistant professor at Temple University Medical School.  He continued on to work as a Project Leader at Adeza Biomedical, a Senior Manager at Genzyme, and eventually served as the Vice President of R&D and Clinical Research at ChemTrak before founding Dx-Sys Inc. He has over 20 publications in peer-reviewed journals and has presented his research in over 20 national and international conferences.

Chakk Ramesha, Ph.D., CTO

Chakk completed is doctorate degree in Biochemistry from the Indian Institute of Science and has since had over 25 years of experience working in Technology and Product Evaluation, Product Development, R&D management, Project Management, and Partnership and Alliance Management. He has previously worked as a scientist at Lederle, a Senior Scientist at Syntex, and a Research Leader at Roche.  He has over 40 publications in peer-reviewed journals.

Satish Menon, Ph.D., Scientific Adviser

Satish completed his doctorate degree in Biochemistry from the Indian Institute of Science and continued his postdoctoral research at Harvard Medical School. He has over 25 years of extensive experience in cancer vaccines, cancer therapies, and humanized antibodies for cancer. He also specializes in Protein Biochemistry Research, Protein Characterization, CMC, Prokaryotic and Eukaryotic cell culture, protein purification, characterization, and early and late stage development of bio-therapeutics.  He has previously worked as a Director at Allergan, Genitope, DNAX/Schering Plough, and as a Senior Director at Geron. He has over 60 publications in peer-reviewed journals.

Radhika Venkatnarayanan, Ph.D., Director – R&D

Radhika completed her doctorate degree in Applied Biology at the Cancer Research Institute at the University of Mumbai. She has over 15 years of experience working with GPCRs and Hybridoma Technology. She began her career as an Associate Scientist at the Fels Institute, Temple University and subsequently worked as an Associate Scientist at Onconova Inc, and as the R&D manager at Multispan.  Her experience in the industry has led to her expertise is cell-based assay development, drug discovery, monoclonal antibody production and recombinant protein expression in bacterial and mammalian systems.  She has over 20 publications in peer-reviewed journals and presentations in national and international conferences.

Priti Hansia, Ph.D., Principal Scientist

Priti completed her doctorate degree in Computational Biology at the Indian Institute of Science, where she specialized in molecular dynamic simulations and quantum chemical calculations. She has been working on the immunodiagnostic R&D at Dx-Sys for over 7 years and has developed an expertise in epitope prediction using computational methods, process development and manufacturing. She has over 10 publications in peer-reviewed papers and presentations in national and international conferences.

Comments are closed